New dialysis filter shows promise in small kidney study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ESRD Patients aged 18 years or older * Patients able to give informed consent (IC) and interested to participate in the study * Stable (according to the investigator) on hemodialysis for more than 3 months with previous treatments of 3x weekly hemodialysis or hemodiafiltration * Stable hemoglobin between 10 and 12 g/dl in the most recent two consecutive blood draws * Stable anticoagulation and ESA regimen with no dosing modifications in the past 1 month * Patients who have an adequate AVF or graft, capable of providing a blood flow rate of at least 300 mL/min according to sessions conducted in past month Exclusion Criteria: * Patients who have acute renal failure with the chance for recovery. * Patients who are pre-scheduled for a living kidney transplant within the next two months, who plan a change to PD within the next two months or who require single needle dialysis therapy. * Pregnant and lactating women. * Patients with a history of positive serology tests for Hepatitis B surface antigen, positive Hepatitis C total antibody, HIV and syphilis. * Patients with known hemodynamic instability, anemia (Hgb \< 90 g/L), and/or severe bleeding risks secondary to coagulation disorders. * Patients with active or ongoing infection per investigator's judgement. * Patients with a history of solid tumors requiring anti-cancer therapy in the past or next 6 months or a life expectancy less than 1 year or patients with a history of a hematology neoplasm. * Patients diagnosed with a NYHA Class IV congestive heart failure, or acute coronary syndrome and/or who have suffered a myocardial infarction within three months prior to the start of the study. * Patients with a history of severe mental disorders. * Patients who are currently participating or have previously participated in another interventional clinical trial in the past 4 weeks. * Patients who have had an allergic response to polyarylethersulfone (PAES) or polysulfone membranes or have a history of poor tolerance to dialyzers with synthetic membranes. * Patients with advanced liver, heart or pulmonary disease as judged by the Investigator * Patients with any comorbidity possibly conflicting with the study purpose or procedures as judged by the Investigator.